Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560681 | 1.00 | KDM4E (0.43) | KDM4ESMN1; SMN2ALDH1A1NQO2GAA | |
| SCHEMBL29559836 | 0.87 | NQO2 (0.39) | KDM4ESMN1; SMN2ALDH1A1NQO2GAA | |
| SCHEMBL27319832 | 0.87 | NQO2 (0.39) | KDM4ESMN1; SMN2ALDH1A1NQO2GAA | |
| SCHEMBL19554465 | 0.87 | KDM4E (0.43) | KDM4ESMN1; SMN2ALDH1A1NQO2GAA | |
| SCHEMBL21813966 | 0.82 | KDM4E (0.52) | KDM4EMAPT | |
| SCHEMBL21813402 | 0.82 | KDM4E (0.39) | KDM4ESMN1; SMN2ALDH1A1NQO2GAA | |
| SCHEMBL21814160 | 0.82 | UGT8 (0.42) | GAARAB9A | |
| SCHEMBL28718650 | 0.81 | EIF4EBP1 (0.35) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL22866803 | 0.81 | LMNA (0.37) | KDM4ESMN1; SMN2ALDH1A1NQO2GAA | |
| SCHEMBL29661920 | 0.81 | LMNA (0.37) | KDM4ESMN1; SMN2ALDH1A1NQO2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024131937-A1 | COMPOUND SERVING AS EIF4E INHIBITOR AND USE THEREOF | 南京圣和药业股份有限公司 | 2024-06-27 | — | — | WO | disclosed |
| CN-118239963-A | Compounds as eIF4E inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230108594-A1 | EIF4E-INHIBITING COMPOUNDS AND METHODS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-04-06 | — | — | US | disclosed |
| WO-2022133303-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3994139-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | Effector Therapeutics Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11286268-B1 | EIF4E-inhibiting compounds and methods | EFFECTOR THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286268-B1 | EIF4E-inhibiting compounds and methods | EIF4E, EIF4EBP1, EIF4A1 | KDM4E 393/4885SMN1; SMN2 1169/4885ALDH1A1 4794/4885 |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | KDM4E 647/4885SMN1; SMN2 552/4885ALDH1A1 509/4885 |
| US-20230108594-A1 | EIF4E-INHIBITING COMPOUNDS AND METHODS | EIF4E, EIF4EBP1, EIF4A1 | KDM4E 393/4885SMN1; SMN2 1169/4885ALDH1A1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.